Unanticipated toxicities from anticancer therapies: Survivors’ perspectives

Gandhi, Mona A.; Oishi, Karen; Zubal, B.; Lacouture, Mario E.

doi:10.1007/s00520-009-0769-1

Cited by 75 publications

(87 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high frequency and negative impact on QoL of dermatological toxicities in this population, as described in this and previous studies (Gandhi et al, 2010;Hackbarth et al, 2008;Ra et al, 2013;Sibaud et al, 2016) highlight the need for optimised supportive oncodermatology to be widely accessible to patients both during and after treatment. In addition, the period immediately after treatment has been identified as a time of increased psychosocial distress among survivors (Montazeri et al, 2008;Paraskevi, 2012).…”

Section: Discussionsupporting

confidence: 61%

“…Compared with other common adverse events after chemotherapy, such as gastrointestinal disorders, fatigue and decreased immunity, dAEs frequently cause higher levels of concern among cancer survivors after the end of treatment (Gandhi et al, 2010;Hackbarth et al, 2008;Rosen et al, 2013). Here, we reported a very high prevalence (81%) of grade-1 or 2 xerosis at inclusion in our total study population.…”

Section: Discussionmentioning

confidence: 59%

“…Finally, the efficacy of hydrotherapy was evaluated only in the short term; further studies are required to determine if the benefits of this treatment are maintained in the longer term, 6 months or a T A B L E 3 Prevalence of dermatological AEs by severity (NCI CTCAE version 4.02 grade) in the study population at the beginning of treatment (V2) year after treatment. However, it should be noted that dermatological toxicities stand for the main immediate chemotherapy-induced adverse events, which are often unanticipated by patients (Gandhi et al, 2010;Hackbarth et al, 2008), and are mainly responsible for QoL impairment (Gandhi et al, 2010;Hackbarth et al, 2008;Ra et al, 2013;Sibaud et al, 2016). Besides, our results were confirmed by a large randomised clinical trial (PACThe study) in 251 patients, which investigated hydrotherapy as supportive treatment in women in breast cancer remission, shortly after chemotherapy completion (Kwiatkowski et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies conducted in patients with gynaecologic cancers have identified dAEs as one of the most significant toxicities limiting quality of life (QoL) and as leading factors impairing functional, emotional, physical and social well-being in cancer patients (Gandhi, Oishi, Zubal, & Lacouture, 2010;Hackbarth, Haas, Fotopoulou, Lichtenegger, & Sehouli, 2008;Ra et al, 2013;Sibaud et al, 2016), especially because they often persist long after completion of chemotherapy (Gandhi et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study

et al. 2017

View full text Add to dashboard Cite

This study investigated the efficacy of post-treatment hydrotherapy as supportive care for management of persistent/long-lasting dermatologic adverse events (dAEs) induced in breast cancer survivors by adjuvant therapy, and its impact on quality of life (QoL).Patients in complete remission after standardised (neo)adjuvant chemotherapy, surgery and radiotherapy combination treatment for infiltrating HR+/HER2-breast carcinoma were enrolled in this randomised, multicentre controlled study 1-5 weeks after completing radiotherapy. The control group (CG, n = 33) received best supportive care and the treatment group (HG, n = 35) received 3-weeks of specific hydrotherapy. The primary criterion was change in QoL (QLQ-BR23) after hydrotherapy. Clinical grading of dAEs, cancer-related QoL (QLQ-C30), dermatologic QoL (DLQI) and general psychological well-being (PGWBI) were assessed. Significant dAEs were found at inclusion in both groups (n = 261). Most items showed significantly greater improvement in the HG

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…After subsequent reports confirmed this observation, weight gain was included as a known side effect of adjuvant chemotherapy [2] . Despite this, most women appear to be inadequately informed about this possibility, as demonstrated by one study reporting concern about treatment-associated weight gain in only 27% of survivors prior to therapy [3] . …”

mentioning

confidence: 99%

Weight gain following breast cancer diagnosis: Implication and proposed mechanisms

Makari-Judson

Braun

Jerry

et al. 2014

WJCO

135

106

View full text Add to dashboard Cite

Weight gain occurs in the majority of women following breast cancer treatment. An overview of studies describing weight gain amongst women treated with early to modern chemotherapy regimens is included. Populations at higher risk include women who are younger, closer to ideal body weight and who have been treated with chemotherapy. Weight gain ranges between 1 to 5 kg, and may be associated with change in body composition with gain in fat mass and loss in lean body mass. Women are unlikely to return to pre-diagnosis weight. Possible mechanisms including inactivity and metabolic changes are explored. Potential interventions are reviewed including exercise, dietary changes and pharmacologic agents. Although breast cancer prognosis does not appear to be significantly impacted, weight gain has negative consequences on quality of life and overall health. Future studies should explore change in body composition, metabolism and insulin resistance. Avoiding weight gain in breast cancer survivors following initial diagnosis and treatment should be encouraged.© 2014 Baishideng Publishing Group Inc. All rights reserved.Key words: Breast cancer; Weight gain; Exercise; Survivorship; Insulin resistance Core tip: Weight gain occurs in the majority of women following breast cancer treatment, especially those who are younger, closer to ideal body weight and who have been treated with chemotherapy. Although weight gain may be modest, changes are consistent with sarcopenic obesity. Women are unlikely to return to pre-diagnosis weight. Although the degree of weight gain does not appear to significantly alter prognosis, associated changes in metabolism and inactivity are of concern. Interventions should be promoted to avoid weight gain. INTRODUCTIONWeight gain following a diagnosis of breast cancer has been reported consistently in women treated for breast cancer, but was an unexpected finding when first described Dixon and colleagues in 1978 [1] . After subsequent reports confirmed this observation, weight gain was included as a known side effect of adjuvant chemotherapy [2] . Despite this, most women appear to be inadequately informed about this possibility, as demonstrated by one study reporting concern about treatment-associated weight gain in only 27% of survivors prior to therapy [3] . WHY IS POST-TREATMENT WEIGHT GAIN OF CONCERN?Obesity is a global issue associated with increased risk of developing post-menopausal breast cancer [4] and a worse prognosis at the time of diagnosis [5] . However, the effect of weight gain following a diagnosis of breast cancer is less well understood. While weight gain following diagnosis does not necessarily lead to obesity or its consequences, any impact on breast cancer prognosis and overall health, patient self-image, or quality of life (QoL) would be an undesirable outcome. These outcomes may be interrelated: weight gain can influence other medical conditions such as diabetes, heart disease, hypertension and hypercholesterolemia that may impact overall survival. For example, Erick...

show abstract

Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

IMPORTANCE Endocrine therapy-induced alopecia (EIA) has been anecdotally reported but not systematically described. OBJECTIVE To characterize EIA in patients with breast cancer. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of 112 patients with breast cancer, diagnosed with EIA from January 1, 2009, to December 31, 2016, the patients were examined at the dermatology service in a large tertiary care hospital and comprehensive cancer center. MAIN OUTCOMES AND MEASURES The clinical features, alopecia-related quality of life (QoL), and response to minoxidil of EIA in patients with breast cancer were assessed. Data from the Hairdex Questionnaire was used to assess the impact of the alopecia on patients QoL. Higher score indicates lower QoL (0-100 score). Efficacy of minoxidil was measured at 3 or 6 months by a single-blinded investigator through standardized clinical photographs of the scalp. RESULTS A total of 112 female patients with breast cancer were included (median [range] age, 60 [34-90] years). A total of 104 patients (93%) had standardized clinical photographs; of these, 59 patients (53%) had trichoscopy images available at baseline, and 46 patients (41%) were assessed for response to minoxidil. Alopecia was attributed to aromatase inhibitors in 75 patients (67%) and tamoxifen in 37 (33%). Severity was grade 1 in 96 of 104 patients (92%), and the pattern was similar to androgenetic alopecia. The predominant trichoscopic feature at baseline was the presence of vellus hairs and intermediate-and thick-diameter terminal hair shafts. A negative impact on QoL was reported, with a higher effect in the emotion domain according to the Hairdex score (mean [SD], 41.8 [21.3]; P < .001). After treatment with topical minoxidil, moderate or significant improvement in alopecia was observed in 37 of 46 patients (80%). CONCLUSIONS AND RELEVANCE Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents. A significant negative impact on QoL was reported by patients, despite mostly mild alopecia severity.

show abstract

Unanticipated toxicities from anticancer therapies: Survivors’ perspectives

Cited by 75 publications

References 24 publications

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study

Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study

Weight gain following breast cancer diagnosis: Implication and proposed mechanisms

Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

Contact Info

Product

Resources

About